ENDRA Life Sciences Inc. (NDRA)
NDRA trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1681682/000165495421003302/0001654954-21-003302-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NDRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001681682 |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$11.7M |
| Operating income | -$11.5M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $7.2M |
| Total assets | $8.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These matters raise substantial doubt about the Company's ability to continue as going concern." | 10-Q 2026-08-14 |
| Cash and burn | $1.7M cash; operating cash flow -$1.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,499,838 (2026-08-14); 752,755 a year earlier; 7,481,603 three years earlier. 3y figure adjusted for splits (1-for-1750 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 2; latest 1-for-35 on 2024-11-07 | Source 2024-11-07 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-21 |
| Auditor | RBSM LLP, HOUSTON, Texas, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | $160K | -$928K | $1.7M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$1.3M | -$1.1M | $356K | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | Not filed | -$3.2M | -$1.6M | $762K | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$1.6M | -$1.2M | $794K | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$1.2M | -$1.1M | $1.8M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$1.0M | -$1.3M | $2.1M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | Not filed | -$4.1M | -$1.5M | $3.2M | $0 | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$2.4M | -$1.7M | $4.7M | $0 | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.8% |
| 1 month | -12.5% |
| 3 months | -1.3% |
| Year to date | -2.6% |
| 1 year | -32.9% |
| From 52-week high | -34.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IRIX | IRIDEX Corporation | $0.6878 | -0.32% | $12.1M |
| ITOC | iTonic Holdings Ltd | $1.88 | -5.05% | $13.8M |
| NUWE | Nuwellis Inc. | $4.48 | -8.57% | $2.4M |
| NXL | Nexalin Technology Inc. | $1.56 | +2.30% | $1.9M |
| QTI | QT Imaging Holdings Inc. | $1.80 | -4.26% | $26.4M |
| VBIO | Valion Bio Inc. | $0.5290 | +0.84% | $1.1M |
| ECOR | electroCore Inc. | $4.84 | -7.81% | $44.7M |
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier